Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis
Open Access
- 19 January 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (2), 128
- https://doi.org/10.3390/antibiotics11020128
Abstract
Severe infectious complications remain the main cause of mortality in leukemia patients due to a long period of profound neutropenia. Standardized regimens for antimicrobial, antifungal, and antiviral prophylaxis and therapy in neutropenic patients have improved infection-associated mortality. Nevertheless, many patients are refractory to these multidrug approaches. Tigecycline is a last-resort antibiotic with a broad-spectrum activity; unfortunately, clinical experience in multidrug-resistant febrile neutropenia is limited. The aim was to evaluate the efficacy of tigecycline treatment in comparison to standard treatment in this patient cohort. In this single center analysis, we analyzed the clinical courses of 73 patients with acute leukemia and diagnosis of febrile neutropenia resistant to hospital-based multidrug escalation levels who continued on a standard approach without antibiotics as the last resort (n = 30) or were switched to tigecycline in addition to carbapenem treatment (n = 43). We observed comparable overall response rates (decrease in C-reactive protein or resolution of fever) in both patient cohorts. Switching the antibiotic approach to tigecycline showed lower absolute sepsis (33% vs. 47%, p = 0.235) and infection-associated mortality rates (5% vs. 13%, p = 0.221). Prospective larger randomized studies are necessary to underline these results and to be able to generate reliable statistics.Keywords
This publication has 29 references indexed in Scilit:
- Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitalsInfection, 2013
- The current spectrum of infection in cancer patients with chemotherapy related neutropeniaInfection, 2013
- Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistanceBMC Infectious Diseases, 2013
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacinDiagnostic Microbiology and Infectious Disease, 2009
- Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 casesEuropean Journal of Haematology, 2008
- The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra‐Abdominal Infections: Analysis of Pooled Clinical Trial DataClinical Infectious Diseases, 2005
- Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Tigecycline: A review of a new glycylcycline antibioticJournal of Dermatological Treatment, 2005
- Improved Comorbidity Adjustment for Predicting Mortality in Medicare PopulationsHealth Services Research, 2003